PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth

PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth

Abstract Background Management of bladder cancer (BLCA) has not changed significantly in the past few decades, with platinum agent chemotherapy being used in most cases. Chemotherapy reduces tumor recurrence after resection, but debilitating toxicities render a large percentage of patients ineligibl...

Celý popis

Podrobná bibliografie
Hlavní autoři: Sayani Bhattacharjee, Matthew J. Sullivan, Rebecca R. Wynn, Alex Demagall, Andrew S. Hendrix, Puneet Sindhwani, Firas G. Petros, Nagalakshmi Nadiminty
Médium: Článek
Jazyk:English
Vydáno: BMC 2022-03-01
Edice:BMC Cancer
Témata:
Bladder cancer
Urothelial carcinoma
PARP inhibition
Cisplatin
DNA damage repair
Combination therapy
On-line přístup:https://doi.org/10.1186/s12885-022-09376-9

Internet

https://doi.org/10.1186/s12885-022-09376-9

Podobné jednotky